US 12246064
Method of treating Crohn's disease by administering a triple combination therapy of anti-integrin antibody, adalimumab and methotrexate
granted A61KA61K2039/505A61K2039/54
Quick answer
US patent 12246064 (Method of treating Crohn's disease by administering a triple combination therapy of anti-integrin antibody, adalimumab and methotrexate) held by Takeda Pharmaceutical Company Limited expires Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Takeda Pharmaceutical Company Limited
- Grant date
- Tue Mar 11 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Mar 06 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 15
- CPC classes
- A61K, A61K2039/505, A61K2039/54, A61K2039/545, A61K2300/00